Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity.,Clinical Cancer Research

当前位置： X-MOL 学术 › Clin. Cancer Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity.
Clinical Cancer Research ( IF 11.5 ) Pub Date : 2020-06-01 , DOI: 10.1158/1078-0432.ccr-20-0707
Alexandra O Sokolova _{1,

2,

3} , Evan Y Yu _{1,

2} , Heather H Cheng _{1,

2}

Affiliation

PARP inhibitors (PARPi) are promising in BRCA2 -altered prostate cancer. Data were presented on PARPi efficacy in prostate cancers with alterations in other DNA damage repair genes which suggest low response rates in ATM-, CHEK2-, CDK12 -altered tumors and promising results in PALB2-, RAD51B-, FANCA- , and BRIP1 -altered tumors. See related article by Abida et al., [p. 2487][1] [1]: /lookup/volpage/26/2487?iss=11

中文翻译：

研讨前列腺癌中的PARPi反应：从HR途径到逐个基因的粒度。

PARP抑制剂（PARPi）在BRCA2改变的前列腺癌中很有前途。提出了关于PARPi在前列腺癌中的功效以及其他DNA损伤修复基因的改变的数据，这些数据表明在ATM-，CHEK2-，CDK12改变的肿瘤中应答率低，在PALB2-，RAD51B-，FANCA-和BRIP1改变的肿瘤中有希望的结果肿瘤。参见Abida等人的相关文章，[p。2487] [1] [1]：/ lookup / volpage / 26/2487？iss = 11

更新日期：2020-06-01

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>